 |
 Video: What is a Stock Split?
|
|
|
| Corvus Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of immune modulator product candidates to treat solid cancers, T-cell lymphomas, autoimmune diseases and infectious diseases. Co.'s lead product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73. Co.'s next product candidate, CPI-818, is a selective, covalent inhibitor of ITK and is in a multi-center Phase 1/1b clinical trial in patients with various malignant T-cell lymphomas. Co.'s third product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine. According to our Corvus Pharmaceuticals stock split history records, Corvus Pharmaceuticals has had 0 splits. | |
|
Corvus Pharmaceuticals (CRVS) has 0 splits in our Corvus Pharmaceuticals stock split history database.
Looking at the Corvus Pharmaceuticals stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Corvus Pharmaceuticals shares, starting with a $10,000 purchase of CRVS, presented on a split-history-adjusted basis factoring in the complete Corvus Pharmaceuticals stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
03/24/2016 |
|
| End date: |
04/26/2024 |
|
| Start price/share: |
$14.25 |
|
| End price/share: |
$1.45 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-89.82% |
|
| Average Annual Total Return: |
-24.59% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$1,017.84 |
|
| Years: |
8.10 |
|
|
|
|
|
